Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Company profile
Ticker
TOVX
Exchange
Website
CEO
Steven Shallcross
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC, Synthetic Biologics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Pipex Therapeutics, Inc. • Effective Pharmaceuticals, Inc. • Solovax, Inc. • CD4 Biosciences, Inc. • Epitope Pharmaceuticals, Inc. • Healthmine, Inc. • Putney Drug Corp. • Synthetic Biomics, Inc. • VCN Biosciences, S.L. ...
IRS number
133808303
TOVX stock data
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results
11 May 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
30 Mar 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
10 Mar 23
8-K
Regulation FD Disclosure
16 Feb 23
8-K
Regulation FD Disclosure
17 Jan 23
8-K
Regulation FD Disclosure
9 Jan 23
8-K
Entry into a Material Definitive Agreement
23 Dec 22
8-K
Departure of Directors or Certain Officers
20 Dec 22
Transcripts
TOVX
Earnings call transcript
2022 Q3
10 Nov 22
TOVX
Earnings call transcript
2022 Q2
11 Aug 22
TOVX
Earnings call transcript
2022 Q1
16 May 22
TOVX
Earnings call transcript
2021 Q4
17 Mar 22
TOVX
Earnings call transcript
2021 Q3
3 Nov 21
TOVX
Earnings call transcript
2021 Q2
6 Aug 21
TOVX
Earnings call transcript
2021 Q1
6 May 21
TOVX
Earnings call transcript
2020 Q4
5 Mar 21
TOVX
Earnings call transcript
2020 Q3
10 Nov 20
TOVX
Earnings call transcript
2020 Q2
6 Aug 20
Latest ownership filings
4
STEVEN A SHALLCROSS
13 Feb 23
4
STEVEN A SHALLCROSS
3 Feb 23
4
STEVEN A SHALLCROSS
26 Jan 23
4
STEVEN A SHALLCROSS
23 Jan 23
4
STEVEN A SHALLCROSS
3 Jan 23
4
Jeffrey J Kraws
16 Dec 22
4
Jeffrey Alan Wolf
16 Dec 22
4
JOHN J MONAHAN
16 Dec 22
4
STEVEN A SHALLCROSS
16 Dec 22
4
Francis Tufaro
16 Dec 22
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 36.18 mm | 36.18 mm | 36.18 mm | 36.18 mm | 36.18 mm | 36.18 mm |
| Cash burn (monthly) | 1.90 mm | 1.72 mm | 1.73 mm | 1.88 mm | 1.87 mm | 1.65 mm |
| Cash used (since last report) | 4.21 mm | 3.80 mm | 3.82 mm | 4.15 mm | 4.13 mm | 3.65 mm |
| Cash remaining | 31.97 mm | 32.38 mm | 32.36 mm | 32.03 mm | 32.04 mm | 32.53 mm |
| Runway (months of cash) | 16.8 | 18.8 | 18.7 | 17.1 | 17.1 | 19.7 |
Institutional ownership, Q4 2022
27.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 24 |
| Opened positions | 4 |
| Closed positions | 5 |
| Increased positions | 6 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 393.38 mm |
| Total shares | 4.18 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Custodian Ventures | 2.22 mm | $1.96 mm |
| Iroquois Capital Management | 908.20 k | $247.00 k |
| Vanguard | 525.37 k | $238.94 mm |
| BLK Blackrock | 190.17 k | $86.49 mm |
| Geode Capital Management | 116.30 k | $52.00 k |
| STT State Street | 48.69 k | $22.15 mm |
| NTRS Northern Trust | 35.70 k | $16.24 mm |
| Renaissance Technologies | 32.51 k | $15.00 k |
| Virtu Financial | 28.97 k | $13.00 k |
| Bridgeway Capital Management | 28.53 k | $12.98 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Feb 23 | Steven A Shallcross | Common Stock | Buy | Acquire P | No | No | 1.043 | 25,000 | 26.07 k | 210,000 |
| 2 Feb 23 | Steven A Shallcross | Common Stock | Buy | Acquire P | No | No | 0.9405 | 25,000 | 23.51 k | 185,000 |
| 25 Jan 23 | Steven A Shallcross | Common Stock | Buy | Acquire P | No | No | 0.873 | 25,000 | 21.83 k | 160,000 |
| 20 Jan 23 | Steven A Shallcross | Common Stock | Buy | Acquire P | No | No | 0.7482 | 25,000 | 18.71 k | 135,000 |
| 29 Dec 22 | Steven A Shallcross | Common Stock | Buy | Acquire P | No | No | 0.437 | 100,000 | 43.70 k | 110,000 |
News
Earnings Scheduled For May 11, 2023
11 May 23
Theriva Biologics Q1 EPS $(0.30) Beats $(0.32) Estimate. Cash at Q1 $36.1M - To Provide Runway Till 3Q24
11 May 23
Theriva Biologics Earnings Preview
10 May 23
Theriva Biologics FY EPS $(1.31) Up From $(1.90) YoY; $41.8M In Cash Expected To Provide Runway Into Q3 2024
30 Mar 23
Earnings Scheduled For March 30, 2023
30 Mar 23
Press releases
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
13 Apr 23
Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
30 Mar 23
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
24 Mar 23
Theriva Biologics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results
20 Mar 23